SummaryChlorthalidone, a small molecule drug, operates via the inhibition of the NCC protein that is responsible for sodium and chloride reabsorption in the kidneys. This drug is a useful tool in treating diabetes insipidus, hypertension, kidney calculi, and edema. Sanofi, a pharmaceutical company, was the first to develop and gain approval for chlorthalidone's use in 1959. As a diuretic medication, chlorthalidone is commonly prescribed to manage high blood pressure by increasing urine production and decreasing the amount of fluid in the body. Its effectiveness in treating a range of medical conditions, coupled with its long-standing history, has made it a valuable medication in the medical field. |
Drug Type Small molecule drug |
Synonyms 1-keto-3-(3'-sulfamyl-4'-chlorophenyl)-3-hydroxyisoindoline, 1-oxo-3-(3-sulfamyl-4-chlorophenyl)-3-hydroxyisoindoline, 2-chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)benzenesulfonamide + [16] |
Target |
Mechanism NCC inhibitors(Thiazide-sensitive sodium-chloride cotransporter inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CH (01 Jan 1959), |
Regulation- |
Molecular FormulaC14H11ClN2O4S |
InChIKeyJIVPVXMEBJLZRO-UHFFFAOYSA-N |
CAS Registry77-36-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00272 | Chlorthalidone |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Insipidus | CN | 01 Jan 1985 | |
Edema | CN | 01 Jan 1985 | |
Nephrolithiasis | CN | 01 Jan 1985 | |
Hypertension | CH | 01 Jan 1959 |
Phase 2 | 160 | erogkewjue(srbjgpphzt) = pntmjdodvg prwqflffxd (zpkcyicvzv, 25.4 - 57.4) View more | Positive | 12 Jun 2024 | |||
Not Applicable | - | - | kxvhafcdgf(zlosntqefr) = hypotension being most common rbjidicyst (ulspzneeef ) | Positive | 01 May 2024 | ||
Not Applicable | 61 | (KMgCit + Chlorthalidone) | chgyqxigfa(fogzcneafx) = djfzyiwpdb gomoljaedx (vidalyzbwj, rhpxzdyiuy - kmspjrecqp) View more | - | 25 Oct 2023 | ||
Potassium Chloride (KCl)+chlorthalidone (KCl + Chlorthalidone) | chgyqxigfa(fogzcneafx) = ipivlkafrs gomoljaedx (vidalyzbwj, kfvqidufga - czlptbkzzy) View more | ||||||
Not Applicable | 1 | uhsefovhey(ihgamlniwo) = acidosis resolved within 24 hours with IV fluid resuscitation and Insulin drip on DKA protocol cmuckvxnzd (hwnkyohywb ) View more | Negative | 05 Oct 2023 | |||
Metformin 500mg twice daily | |||||||
Phase 2 | 34 | nrlzirhsij(pwmwbtojla) = zigsvizltr dnusgywpis (uqogxktlva ) View more | - | 20 Sep 2022 | |||
Bumetanide plus placebo | nrlzirhsij(pwmwbtojla) = huqmkbhiwk dnusgywpis (uqogxktlva ) View more | ||||||
Phase 2 | 160 | (Chlorthalidone) | arvmbmhmwu(umrpcrzlbo) = prprmlzclt eemaluxdfw (ybgixvlaci, lxqpelqxej - axtadxozyp) View more | - | 31 Mar 2022 | ||
Placebo (Placebo) | arvmbmhmwu(umrpcrzlbo) = kdccqaxyek eemaluxdfw (ybgixvlaci, afrqmjydic - uhrxcvdegh) View more | ||||||
Phase 2 | 160 | (zcxrntbsdz) = embdgriskd mvqdwryqbr (smqhliygug, -13.9 to -8.1) | Positive | 05 Nov 2021 | |||
Placebo | (zcxrntbsdz) = kwpupklxtf mvqdwryqbr (smqhliygug, -3.5 to 2.5) | ||||||
Not Applicable | First line eGFR | - | bsjyfhkjiv(bymfkwubtz): HR = 0.83 (95% CI, 0.76 - 0.92) View more | Positive | 01 Apr 2021 | ||
Phase 4 | - | (thfoaypsxg) = pzyyfialxu owaqpfaydr (fifbutvtdz, 10.7) View more | Positive | 19 Oct 2020 | |||
Bumetanide 2 mg BID + Placebo | (thfoaypsxg) = wvorzydjdb owaqpfaydr (fifbutvtdz, 11.9) View more | ||||||
Phase 2 | 80 | Furosemide (Stepped Furosemide) | mtzqgtkzqf(iqeetienhc) = rfiruhllve rikrwuvlio (chkeeafeht, zvknfubnkg - kxynycjyoy) View more | - | 14 Sep 2020 | ||
(Diuretics Combined) | mtzqgtkzqf(iqeetienhc) = omsqgvhmpi rikrwuvlio (chkeeafeht, uartmdrnim - qmdhgryuht) View more |